Ipek Erdogan-Trinkaus - 12 Jan 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Commercial Officer
Signature
/s/ James R. Gruber
Issuer symbol
ETON
Transactions as of
12 Jan 2026
Net transactions value
$0
Form type
4
Filing time
14 Jan 2026, 18:05:48 UTC
Previous filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Erdogan-Trinkaus Ipek Chief Commercial Officer C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 14 Jan 2026 0002047026

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Employee Stock Option (Right to Buy) Award $0 +40,655 +49% $0.000000 123,878 12 Jan 2026 Common Stock 40,655 $15.47 Direct F1
transaction ETON Restricted Stock Units Award $0 +25,856 +21% $0.000000 149,734 12 Jan 2026 Common Stock 25,856 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
F2 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F3 The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The signing person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.